Han Lin in Financial Times: ‘If we look at how China looks at Starmer’s visit, I don’t think they’re looking for British factories to be set up in China, I think they want more British capabilities . . . finance, asset management, life sciences, education, green standards’
Han Lin, China managing director for the Asia Group, said it was “too difficult” for UK banks to compete domestically ...
Media
Commentary
TAG Paper: Observations on Drug Pricing and Innovation in Japan
Full Paper (English): TAG Paper: Observations on Drug Pricing and Innovation in Japan ENG
Full Paper (Japanese): TAG Paper: Observations on Drug Pricing and Innovation in Japan JPN
Key Findings
As the Government of Japan (GOJ) seeks to re-invigorate Japan’s pharmaceutical industry as a sector for innovation and growth, it can make impactful changes to specific pricing policies that will support Japanese patients’ access to the most innovative medicines.
The Asia Group (TAG) has identified two specific pharmaceutical pricing measures that directly undermine the government’s goal of promoting startups and bringing innovative new pharmaceutical products to market. The negative impact of these policies is particularly severe for innovative drugs for rare diseases, for which there are often no alternative treatments:
The intended purpose of these rules is to improve transparency in a product’s total cost and provide incentives for drug launches in Japan. But the two-fold impact of these rules, particularly penalizing new market entrants and foreign entrants, has undermined the intended effect of these measures.
Eliminating these two specific punitive pricing policies represents “low-hanging fruit” for policy change, which can have an immediate impact on the availability of novel drugs, while having a relatively low impact on Japan’s healthcare budget. These changes will stimulate future successful launches and early entrance to Japan, benefitting patients.
Listen on:
Related Posts
Han Lin in Financial Times: ‘If we look at how China looks at Starmer’s visit, I don’t think they’re looking for British factories to be set up in China, I think they want more British capabilities . . . finance, asset management, life sciences, education, green standards’
Han Lin interviewed by BBC on PM Starmer’s Beijing visit
Kurt Campbell’s op-ed on U.S.-China relations featured in The New York Times
Shailender Arya in The Hindu Business Line: ‘The conclusion of security and defence partnership between India and EU provides strategic intent and intimate policy guidance for closer defence industrial cooperation between the Indian and European defence industries’